Emerging evidence suggests that alterations in CP structure and function are closely linked to the pathophysiology of Alzheimer’s disease (AD), highlighting its potential as a biomarker for disease progression and severity (Lu et al., 2023; Butler et al., 2023; Althubaity et al., 2022). This evidence concerns the gene CP and Alzheimer disease.